eMedicine Specialties > Emergency Medicine > Infectious Diseases

Lymphogranuloma Venereum

Author: Andrew C Bushnell, MD, FACEP, Department of Surgery, Division of Emergency Medicine, Assistant Professor, University of Vermont College of Medicine
Contributor Information and Disclosures

Updated: Aug 17, 2009

Introduction

Background

Lymphogranuloma venereum (LGV) is a sexually transmitted disease that primarily infects the lymphatics.

The disease originally was described in 1833 by Wallace. It was defined as a clinical and pathological entity in 1913 by Durand, Nicolas, and Favre.

LGV synonyms include lymphopathia venerea, tropical bubo, climatic bubo, strumous bubo, poradenitis inguinales, Durand-Nicolas-Favre disease, and lymphogranuloma inguinale.

Pathophysiology

LGV is caused by serovars L1, L2, and L3 of Chlamydia trachomatis. It gains entrance through skin breaks and abrasions, or it crosses the epithelial cells of mucous membranes. The organism travels via the lymphatics to multiply within mononuclear phagocytes in regional lymph nodes.

Transmission is predominantly sexual. However, transmission by fomites, nonsexual personal contact, and laboratory accidents has been documented. The creation of aerosols of this organism has been associated with infection and pulmonary symptoms.

LGV occurs in 3 stages. The majority of LGV infections in the primary and secondary stages may go undetected.

The primary stage is marked by the formation of a painless herpetiform ulceration at the site of inoculation.

The secondary stage is classically described as the inguinal syndrome in men, characterized by painful inguinal lymphadenitis and associated constitutional symptoms.

  • Tender inguinal lymphadenopathy, usually unilateral, is the most common clinical manifestation.
  • Lymphatic drainage from the penis is through the inguinal lymph nodes; thus, heterosexual men are affected most often in the inguinal lymph nodes.
  • Homosexual men and women who are receptive to anal sex may develop perirectal and pelvic lymph node involvement. In women, these nodes may also become involved as a result of lymphatic spread from the cervix and posterior vaginal wall.
  • Early in the course of the disease, the nodes appear fleshy and show diffuse reticulosis.
  • Later, suppurative granulomatous lymphadenitis and perilymphadenitis occur with matting of the nodes. Frequently, these nodes coalesce to form stellate abscesses.
  • Histologically, these abscesses are nearly diagnostic, but the clinical appearance may be similar to those seen in other infections, including catscratch fever and mycobacterial granulomatous infections.

The tertiary stage of LGV occurs years after the initial infection. In this stage, an anogenitorectal syndrome may occur with resultant rectal stricture or elephantiasis of the genitalia.

  • This syndrome is found predominantly in women and homosexual men, because of the location of the involved lymphatics.
  • This late stage is characterized by proctocolitis, which is caused by hyperplasia of intestinal and perirectal lymphatic tissue.
  • This inflammation forms perirectal abscesses, ischiorectal abscesses, rectovaginal fistulas, anal fistulas, and rectal stricture. In very late stages, fibrosis and granulomas are characteristic.
  • Chlamydial organisms are scarce at this stage.

Extragenital inoculation sites can produce regional lymphadenopathy. Examples are of mediastinal lymphadenopathy from inhalation of C trachomatis, or submandibular and cervical chain lymphadenopathy following inoculation after oral sex.

Frequency

United States

Sporadic cases occur in North America, Australia, and most of Asia. Most cases in the United States involve recent travel to an endemic area where the patient was sexually active; therefore, obtaining a travel history is important. Historically, the average number of LGV cases in the United States has been fewer than 600 per year.

International

LGV is endemic in East and West Africa, India, Southeast Asia, South America, the Caribbean, and Australia.1 Since 2003, an increasing epidemic of LGV with the L2 serovar has occurred in men who have sex with men in western Europe.

Mortality/Morbidity

  • Given appropriate treatment, patients usually have complete resolution of symptoms.
  • Death can occur from tertiary LGV if complete bowel obstruction from rectal stricture leads to perforation; this is rare, however.

Sex

LGV is diagnosed in men up to 6 times more frequently than in women.

Age

LGV infection is most common in the second and third decades when sexual activity is highest.

Clinical

History

  • Primary lymphogranuloma venereum (LGV)
    • The primary lesion of LGV occurs after an incubation period of 3-21 days following an exposure.
    • The initial lesion may be a painless papule, shallow erosion, ulcer, or grouping of lesions with a herpetiform appearance.
    • If the primary lesion is in the urethra, symptoms of a nonspecific urethritis may occur.
    • The most common sites of primary infection in men include the coronal sulcus, frenulum, prepuce, penis, urethra, glans, and scrotum.
    • In women, the most common sites of the primary lesion include the posterior vaginal wall, fourchette, posterior lip of the cervix, and vulva.
    • The primary lesion is noticed in one third of affected men but rarely is observed in affected women.
    • Primary lesions of the mouth can result from oral sexual exposure.
  • Secondary LGV
    • The secondary stage of LGV occurs after a usual incubation period of 10-30 days, but it may be up to 6 months. This stage is characterized by the formation of enlarged, tender regional lymph nodes known as buboes.
    • Patients may experience constitutional symptoms, which can include fever, headache, malaise, chills, nausea, vomiting, and arthralgias.
  • Tertiary LGV
    • This late stage is characterized by proctocolitis.
    • Symptoms include anal pruritus, bloody mucopurulent rectal discharge, fever, rectal pain, tenesmus, constipation, pencil-thin stools, and weight loss.

Physical

Often, the diagnosis is considered initially on the basis of physical findings. Clinical findings of large fluctuant buboes or draining sinuses are suggestive of the diagnosis of LGV. The presence of rectal stricture and/or perineal deformity in a young woman is highly suggestive of LGV.

  • Primary LGV
    • The initial lesion may be a painless papule, shallow erosion, ulcer, or herpetiform grouping of lesions.
    • A cordlike lymphangitis of the dorsal penis may develop in primary LGV. This may progress to the formation of a solitary, large, tender lymphoid nodule, or bubonulus. These bubonuli may rupture to form sinuses and/or fistulas.
  • Secondary LGV
    • Buboes, which are enlarged, tender regional lymph nodes, may be present.
    • The location of lymph node involvement is related directly to the site of the primary lesion.
      • Inguinal lymphadenopathy occurs if the primary lesion involves the anterior vulva, penis, or urethra.
      • Perirectal and pelvic lymphadenopathy result if the primary lesion involves the posterior vulva, vagina, or anus.
      • Lymphadenitis of the submaxillary and cervical glands occurs if the site of primary inoculation is the mouth.
    • Seventy-five percent of all patients have deep iliac nodal involvement, which seldom suppurates.
    • In the classic presentation of the heterosexual man with inguinal lymph node involvement, a groove depression (groove sign) overlying the inguinal ligament is noted. This is caused by proliferation of inguinal and femoral lymph nodes, which are separated by the inguinal (Poupart) ligament. However, this presentation is seen in only 20% of affected men.
    • Two thirds of patients with inguinal involvement have unilateral inguinal bubo formation with edema and erythema of the overlying skin.
      • Frequently these nodes coalesce to form stellate abscesses.
      • One third of these abscesses rupture; two thirds involute. Prior to a rupture, the skin overlying the buboes may become a dark livid color. After a rupture, pain decreases; however, a discharge may continue for weeks to months with the formation of a fistula or sinus tract.
    • Cutaneous manifestations may accompany infection, including erythema multiforme, scarlatiniform eruption, urticaria, and, in 10% of cases, erythema nodosum.
    • Complications of LGV that may be noted on physical examination include arthritis, conjunctivitis, and hepatomegaly. Pericarditis, pneumonia, and meningoencephalitis rarely occur.
  • Tertiary LGV
    • This stage is characterized by proctocolitis.
    • Lymphorrhoids or perianal condylomata may be observed on examination of the rectum. These structures appear similar to hemorrhoids and are the result of an obstruction of lymphatics. They are composed of dilated lymph vessels with perilymphatic inflammation.
    • Rectal examination at this stage also may reveal a granular mucosa and palpable, enlarged lymph nodes under the bowel wall. Stricture usually occurs 2-5 cm above the anocutaneous margin, and digital examination above the stricture may reveal smooth healthy mucosa.
    • In very late stages, fibrosis and granulomas are characteristic.
      • In women, esthiomene (eating away) occurs, which results in hypertrophic, chronic granulomatous enlargement of the vulva and subsequent ulceration. This may not appear for 1-20 years after the primary infection.
      • In men, elephantiasis of the genitalia can occur.

Causes

  • The causal organism is C trachomatis, serovars L1, L2, and L3.
  • Serovar L2 is the most common cause.
  • Risk factors
    • Unprotected sex
    • Anal intercourse
    • Residing in or visiting tropical/developing countries
    • Prostitution

More on Lymphogranuloma Venereum

Overview: Lymphogranuloma Venereum
Differential Diagnoses & Workup: Lymphogranuloma Venereum
Treatment & Medication: Lymphogranuloma Venereum
Follow-up: Lymphogranuloma Venereum
References
Further Reading

References

  1. Lee DM, Fairley CK, Owen L, Horvath L, Chen MY. Lymphogranuloma venereum becomes an established infection among men who have sex with men in Melbourne. Aust N Z J Public Health. Feb 2009;33(1):94. [Medline].

  2. Halse TA, Musser KA, Limberger RJ. A multiplexed real-time PCR assay for rapid detection of Chlamydia trachomatis and identification of serovar L-2, the major cause of Lymphogranuloma venereum in New York. Mol Cell Probes. Oct 2006;20(5):290-7. [Medline].

  3. [Guideline] Behavioral counseling to prevent sexually transmitted infections: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. Oct 7 2008;149(7):491-6, W95. [Medline].

  4. Bremer V, Meyer T, Marcus U, Hamouda O. Lymphogranuloma venereum emerging in men who have sex with men in Germany. Euro Surveill. Sep 2006;11(9):152-4. [Medline].

  5. CDC. Lymphogranuloma venereum among men who have sex with men--Netherlands, 2003-2004. MMWR Morb Mortal Wkly Rep. Oct 29 2004;53(42):985-8. [Medline].

  6. [Guideline] Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. Aug 4 2006;55(RR-11):1-94. [Medline].

  7. Fitzpatrick TB, Johnson RA, Polano MK, et al. Color Atlas and Synopsis of Clinical Dermatology. McGraw-Hill Inc; 1992:398-400.

  8. Gilleece Y, Sullivan A. Management of sexually transmitted infections in HIV positive individuals. Curr Opin Infect Dis. Feb 2005;18(1):43-7. [Medline].

  9. Herida M, de Barbeyrac B, Sednaoui P, Scieux C, Lemarchand N, Kreplak G. Rectal lymphogranuloma venereum surveillance in France 2004-2005. Euro Surveill. Sep 2006;11(9):155-6. [Medline].

  10. Jones R. Chlamydia trachomatis (trachoma, perinatal infections, lymphogranuloma venereum, and other genital infections). In: Mandell G, Bennett J and Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. Churchhill-Livingston; 1995:1679-93.

  11. Kropp RY, Wong T. Emergence of lymphogranuloma venereum in Canada. CMAJ. Jun 21 2005;172(13):1674-6. [Medline].

  12. Mabey D, Peeling RW. Lymphogranuloma venereum. Sex Transm Infect. Apr 2002;78(2):90-2. [Medline].

  13. Perine P, Osoba A. Lymphogranuloma venereum. In: Holmes K, Mardh P, Sparling P, eds. Sexually Transmitted Diseases. New York, NY: McGraw-Hill Inc; 1990:195-202.

  14. Pointer J. Genital infections. In: Rosen P, Barkin R, Braen G, eds. Emergency Medicine Concepts and Clinical Practice. 3rd ed. Mosby-Year Book; 1992:1966.

  15. Ronald A, Alfa M. Chancroid, lymphogranuloma venereum, and granuloma inguinale. In: Gorbach S, Bartlett J, and Blacklow N, eds. Infectious Diseases. 2nd ed. Philadelphia, Pa: WB Saunders Co;1998:1012-3.

  16. Sparling P. Sexually transmitted disease. In: Wyngaarden J, Smith L, and Bennett J, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia, Pa: WB Saunders Co; 1992:1759-61.

  17. Stamm W, Holmes K. Chlamydial infections. In: Wilson J, Braunwald E, Isselbacher K, eds. Harrison's Principles of Internal Medicine. 12th ed. New York, NY: McGraw-Hill Inc; 1991:767-8.

  18. Stark D, van Hal S, Hillman R, Harkness J, Marriott D. Lymphogranuloma venereum in Australia: anorectal Chlamydia trachomatis serovar L2b in men who have sex with men. J Clin Microbiol. Mar 2007;45(3):1029-31. [Medline].

  19. van de Laar MJ. The emergence of LGV in western Europe: what do we know, what can we do?. Euro Surveill. Sep 2006;11(9):146-8. [Medline].

  20. van de Laar MJ, Fenton KA, Ison C,. Update on the European lymphogranuloma venereum epidemic among men who have sex with men. Euro Surveill. 2005;10(6):E050602.1. [Medline].

  21. van de Laar MJ, Koedijk FD, Gotz HM, de Vries HJ. A slow epidemic of LGV in the Netherlands in 2004 and 2005. Euro Surveill. Sep 2006;11(9):150-2. [Medline].

  22. van Weel J. Rare sexually transmitted disease hits Europe. Lancet Infect Dis. Dec 2004;4(12):720. [Medline].

  23. Von Lichtenberg F. Infectious disease. In: Cotran R, Kumar V, and Robbins S, eds. Robbins Pathologic Basis of Disease. 4th ed. Philadelphia, Pa: WB Saunders Co; 1989:328.

  24. Ward H, Martin I, Macdonald N, Alexander S, Simms I, Fenton K. Lymphogranuloma venereum in the United kingdom. Clin Infect Dis. Jan 1 2007;44(1):26-32. [Medline].

Further Reading

Clinical guidelines

New York State Department of Health. Lymphogranuloma venereum (LVG). New York (NY): New York State Department of Health; 2007 Aug. 11 p.

Clinical Effectiveness Group, British Association for Sexual Health and HIV (BASHH). National guideline for the management of lymphogranuloma venereum (LVG). London (UK): British Association for Sexual Health and HIV (BASHH); 2006. 14 p.

Herring A, Richens J, LGV Incident Group, Health Protection Agency. Lymphogranuloma venereum (LGV). In: Ross J, Ison C, Carder C, Lewis D, Mercey D, Young H. Sexually transmitted infections: UK national screening and testing guidelines. London (UK): British Association for Sexual Health and HIV (BASHH); 2006 Aug. p. 57-62.

U.S. Preventive Services Task Force. Behavioral counseling to prevent sexually transmitted infections: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008 Oct 7;149(7):491-6, W95. 3

Keywords

lymphogranuloma venereum, lymphopathia venerea, tropical bubo, climatic bubo, strumous bubo, poradenitis inguinales, Durand-Nicolas-Favre disease, lymphogranuloma inguinale, LGV, sexually transmitted disease, STD, Chlamydia trachomatis, C trachomatis

Contributor Information and Disclosures

Author

Andrew C Bushnell, MD, FACEP, Department of Surgery, Division of Emergency Medicine, Assistant Professor, University of Vermont College of Medicine
Andrew C Bushnell, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Medical Editor

Eric M Kardon, MD, FACEP, Attending Emergency Physician, Georgia Emergency Medicine Specialists; Physician, Division of Emergency Medicine, Athens Regional Medical Center
Eric M Kardon, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Jeter (Jay) Pritchard Taylor III, MD, Compliance Officer, Attending Physician, Emergency Medicine Residency, Department of Emergency Medicine, Palmetto Health Richland, University of South Carolina; Medical Director, Department of Emergency Medicine, Palmetto Health Baptist
Jeter (Jay) Pritchard Taylor III, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital
Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: WebMD Salary Employment

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.